Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma

This study has been completed.
Sponsor:
Collaborators:
Millennium Pharmaceuticals, Inc.
Celgene Corporation
Information provided by (Responsible Party):
Pierluigi Porcu, Ohio State University Comprehensive Cancer Center
ClinicalTrials.gov Identifier:
NCT01129180
First received: May 17, 2010
Last updated: December 2, 2013
Last verified: December 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: December 2012
  Primary Completion Date: May 2012 (Final data collection date for primary outcome measure)